Cover Image
市場調查報告書

何杰金氏淋巴瘤的流行病學的預測 ∼2024年

EpiCast Report: Hodgkin's Lymphoma - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 345026
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
何杰金氏淋巴瘤的流行病學的預測 ∼2024年 EpiCast Report: Hodgkin's Lymphoma - Epidemiology Forecast to 2024
出版日期: 2015年10月13日 內容資訊: 英文 52 Pages
簡介

何杰金氏淋巴瘤,為淋巴瘤之一,是影響淋巴系統的癌症症狀,在兒童及成人雙方發病。是從白血球的異常增生開始,透過淋巴系統擴大引起身體免疫系統障礙的疾病。何杰金氏淋巴瘤的發病數量在7大市場中預期從2014年的23,662件到2024年增加到28,397件。今後10年年複合成長率成為2%。

本報告提供何杰金氏淋巴瘤市場相關調查、風險因素等概要與7大市場(美國、法國、德國、義大利、西班牙、英國、日本)的過去10年的疫情趨勢、性別、各年齡的預測彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
  • 全球的趨勢
    • 發病率
    • 7大市場上存活率
  • 預測方法
    • 採用的資訊來源
    • 未採用的資訊來源
    • 假設與預測方法:確診發病數量
    • 5年趨勢
    • 各臨床階段
    • 各細胞
    • 難治性/復發
  • 流行病學的預測
    • 確診發病數量
    • 各年齡
    • 性別
    • 年齡標準化的發病率
    • 診斷時的各臨床階段
    • 各細胞
    • 難治性/復發∼CRT
    • 自體造血幹細胞移植
    • 復發∼自體造血幹細胞移植
    • 5年趨勢
  • 考察
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考文件
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER096-15

Hodgkin's lymphoma (HL), also known as Hodgkin's disease, is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, which spreads beyond the lymphatic system and impairs the body's immune system.

According to the American Cancer Society (ACS), HL can start anywhere in the lymphoid tissue of body, but quite often starts in the upper part of body with main sites in the neck, the chest, or under the arms. HL mostly spreads through lymph vessels to other lymph nodes, and in advanced stages can even invade the bloodstream and spread to other organs including the liver, lungs, and bone marrow. The most common symptoms of HL include enlarged lymph nodes under the skin of the neck, under the arm, or in the groin, fever (which can come and go over several days or weeks) without an infection; drenching night sweats, and weight loss.

To forecast the diagnosed incident cases and five-year diagnosed prevalent cases of HL in 7MM, GlobalData epidemiologists obtained data from population-based studies that provided country-specific data in each of the 7MM. In addition, GlobalData epidemiologists used the staging system for HL known as the Cotswold system, which is a modification of the older Ann Arbor system, to segment the diagnosed incident cases of HL in the 7MM into stages I, II, III, and IV.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of HL in the 7MM from 23,662 diagnosed incident cases in 2014 to 28,397 diagnosed incident cases in 2024 at an Annual Growth Rate (AGR) of 2%. The increase in the diagnosed incident cases of HL was partly attributed to the moderately rising trend in the incidence of HL in the 7MM, combined with changes in the population demographics in the respective markets.

Scope

  • The Hodgkin's Lymphoma (HL) EpiCast Report provides an overview of the risk factors and global trends of HL in the 7MM (US, France, Germany, Italy, Spain, UK and Japan). It includes a 10-year epidemiology forecast for the diagnosed incident cases of HL, segmented by age, sex, and clinical stage at diagnosis, and types (classical HL and nodular lymphocyte predominant HL, with classical HL further segmented into subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) in these markets. In addition, GlobalData epidemiologists provide a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HL, as well as the number of HL diagnosed incident cases refractory to chemo- and radiation therapy, the number of HL diagnosed incident cases who received autologous stem cell transplantation (ASCT), and HL diagnosed incident cases refractory to ASCT from 2014-2024 in these markets.
  • The HL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hodgkin's Lymphoma (HL) EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HL market.
  • Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HL therapeutics in each of the markets covered.
  • Identify the percentage of HL diagnosed incident cases by type and treatment.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Survival Rates for HL - 7MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, HL Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, HL Five-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis
    • 3.4.6. Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Cellular Types
    • 3.4.7. Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to CRT - 7MM
    • 3.4.8. Forecast Assumptions and Methods, HL Diagnosed Incident Cases Who Received ASCT
    • 3.4.9. Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to ASCT
  • 3.5. Epidemiological Forecast for HL (2014-2024)
    • 3.5.1. Diagnosed Incident Cases of HL
    • 3.5.2. Age-Specific Diagnosed Incident Cases of HL
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of HL
    • 3.5.4. Age-Standardized Diagnosed Incidence of HL
    • 3.5.5. Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis
    • 3.5.6. Diagnosed Incident Cases of HL by Cellular Types
    • 3.5.7. Diagnosed Incident Cases of HL, Refractory/Relapse to CRT
    • 3.5.8. Diagnosed Incident Cases of HL, Receiving ASCT
    • 3.5.9. Diagnosed Incident Cases of HL, Refractory to ASCT
    • 3.5.10. Five-Year Diagnosed Prevalent Cases of HL
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologist
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Cotswold Modification of the Ann Arbor Staging Classification for HL
  • Table 2: Risk Factors and Comorbidities for HL
  • Table 3: Trends in the Age-Standardized Incidence of HL in the US, All Ages, 1998-2007
  • Table 4: Trends in the Age-Standardized Incidence of HL in the 5EU, All Ages, 1998-2007
  • Table 5: Trends in the Age-standardized Incidence of HL in Japan, All Ages, 1998-2007
  • Table 6: Trends in the Five-Year Relative Survival (%) of HL in the 7MM, Both Sexes, 1995-2007
  • Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast of HL Diagnosed Incident Cases
  • Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HL Diagnosed Five-Year Prevalent Cases
  • Table 9: 7MM, Sources of Epidemiological Data Used for the Segmentation of HL Diagnosed Incident Cases by Clinical Stage at Diagnosis
  • Table 10: 7MM, Sources of Epidemiological Data Used for the Segmentation of HL Diagnosed Incident Cases by Cellular Type
  • Table 11: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Refractory to CRT
  • Table 12: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Who Received ASCT
  • Table 13: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Refractory ASCT
  • Table 14: 7MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2014-2024
  • Table 15: 7MM, Age-Specific Diagnosed Incident Cases of HL, Both Sexes, N (Row %), 2014
  • Table 16: 7MM, Sex-Specific Diagnosed Incident Cases of HL, All Ages, N (Row %), 2014
  • Table 17: 7MM, Five-Year Diagnosed Prevalent Cases of HL, Both Sexes, All Ages, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of HL, Both Sexes, N, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of HL, All Ages, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of HL (Cases per 100,000 Population), All Ages, by Sex, 2014
  • Figure 5: 7MM, Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014
  • Figure 6: 7MM, Diagnosed Incident Cases of HL by Cellular Types, All Ages, Both Sexes, N, 2014
  • Figure 7: 7MM, Diagnosed Incident Cases of HL, Refractory to CRT, Both Sexes, All Ages, N, 2014
  • Figure 8: 7MM, Diagnosed Incident Cases of HL, Receiving ASCT, Both Sexes, All Ages, N, 2014
  • Figure 9: 7MM, Diagnosed Incident Cases of HL, Refractory/Relapse to ASCT, Both Sexes, All Ages, N, 2014
  • Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of HL, Both Sexes, All Ages, N, 2014-2024
Back to Top